Last updated: September 23, 2026
XIFAXAN, Bausch Health’s rifaximin product, is one of the largest gastrointestinal specialty drugs in the U.S. market. Its commercial base is concentrated in two approved indications: reduction in hepatic encephalopathy recurrence and treatment of irritable bowel syndrome with diarrhea. U.S. sales have continued to grow despite long-standing generic challenges, supported by high patient switching costs, repeat treatment, physician familiarity and patent litigation that delayed competing launches.
The principal commercial risk is a future loss of exclusivity for the 550 mg product. XIFAXAN is a small-molecule drug, so it faces generic rather than biosimilar competition. Bausch’s most important U.S. protection has shifted from earlier composition patents toward method-of-use and formulation patents, with key listed protection extending into the late 2020s and early 2030s.
How large is the XIFAXAN market?
XIFAXAN is a billion-dollar product with a concentrated revenue base.
Bausch Health reports XIFAXAN within its Salix Pharmaceuticals segment. Company filings show continued year-over-year growth in net product revenue through 2023, with annual XIFAXAN sales reaching approximately $1.1 billion to $1.2 billion in the U.S. market.[1]
| Metric |
XIFAXAN position |
| Active ingredient |
Rifaximin |
| Primary U.S. dosage |
550 mg tablets |
| U.S. manufacturer |
Salix Pharmaceuticals, a Bausch Health company |
| Hepatic encephalopathy indication |
Approved in 2010 |
| IBS-D indication |
Approved in 2015 |
| Approximate annual U.S. revenue |
More than $1 billion |
| Product type |
Small-molecule prescription drug |
| Generic or biosimilar pathway |
ANDA generic pathway |
| Core commercial market |
U.S. gastroenterology and hepatology |
XIFAXAN has two main demand pools:
- Hepatic encephalopathy, where 550 mg twice-daily dosing is used to reduce recurrence.
- IBS-D, where patients receive a 14-day course, with repeat courses permitted for recurrent symptoms.
The hepatic encephalopathy market produces recurring prescription demand because patients with advanced liver disease may remain on chronic preventive therapy. IBS-D produces episodic demand, but repeat treatment and the lack of many comparably effective branded alternatives support retention.
What is the financial trajectory for XIFAXAN?
XIFAXAN has been one of Bausch Health’s most durable growth products.
Bausch’s reported results indicate that XIFAXAN revenue grew from roughly $1.0 billion in the early 2020s to more than $1.1 billion in 2022 and approximately $1.2 billion in 2023, depending on the reporting period and presentation of net revenue.[1] Growth has come from prescription volume, price increases, expanded diagnosis and treatment of hepatic encephalopathy, and continued IBS-D utilization.
Financial drivers
The product’s revenue profile has four important characteristics:
- High gross margin relative to manufacturing cost.
- A chronic hepatic encephalopathy customer base.
- A branded price structure with limited therapeutic substitution.
- Significant dependence on U.S. sales and patent enforcement.
XIFAXAN is more economically important to Salix than its sales alone suggest. Salix’s portfolio also includes TRULANCE, APRISO, MOVIPREP and other gastrointestinal products, but XIFAXAN is the segment’s principal commercial asset. Generic entry would therefore create disproportionate pressure on both Salix revenue and Bausch Health’s consolidated cash flow.
Financial exposure to generic entry
A rapid generic launch could reduce branded volume and price materially within the first 12 to 24 months. The impact would depend on:
- The number of approved ANDAs.
- Whether first-filer exclusivity applies.
- The scope of any launch settlement.
- The availability of authorized generic supply.
- The extent to which prescriptions are written for hepatic encephalopathy versus IBS-D.
- Payer substitution and pharmacy-level switching.
Hepatic encephalopathy prescriptions are likely to be more resilient than short-course IBS-D prescriptions because chronic patients may be transitioned more slowly and physicians may place greater weight on continuity of treatment.
What FDA approvals support XIFAXAN’s commercial position?
The FDA approved XIFAXAN 550 mg tablets in 2010 to reduce the risk of overt hepatic encephalopathy recurrence in adults.[2] The FDA later approved the product for IBS-D in 2015.[3]
| FDA milestone |
Date |
Commercial effect |
| Initial U.S. approval for hepatic encephalopathy |
2010 |
Established chronic-use market |
| IBS-D approval |
2015 |
Added a large outpatient gastrointestinal indication |
| Current marketed strength |
550 mg |
Supports both major U.S. indications |
| Regulatory pathway for competitors |
ANDA |
Permits generic substitution after approval |
XIFAXAN is not a biologic. Biosimilar regulation does not apply. Competitors must file abbreviated new drug applications demonstrating bioequivalence and meeting applicable requirements for the reference product.
The drug’s low systemic absorption may create technical development considerations, but it does not remove the ANDA pathway. Generic applicants must still address formulation, dissolution, bioequivalence and product quality requirements.
What patents protect XIFAXAN?
XIFAXAN’s U.S. patent estate includes rifaximin composition, polymorph, formulation and method-of-use claims. The most commercially relevant protection has centered on the 550 mg product and its approved indications.
Representative U.S. patents associated with XIFAXAN include the following:
| Patent |
General subject matter |
Reported or listed expiration range |
| U.S. Patent No. 7,045,620 |
Rifaximin polymorph and composition protection |
2024, including applicable extensions |
| U.S. Patent No. 8,309,627 |
Rifaximin composition or polymorph protection |
2029 |
| U.S. Patent No. 8,455,246 |
Rifaximin-related formulation or use protection |
2029 |
| U.S. Patent No. 8,624,573 |
Rifaximin formulation or method protection |
2029 |
| U.S. Patent No. 9,278,096 |
Method-of-use protection |
2032 |
| U.S. Patent No. 10,583,155 |
Later formulation or method protection |
2034 |
Expiration dates can differ by patent term adjustment, pediatric exclusivity, terminal disclaimers and the specific Orange Book listing. The commercial relevance of each patent also depends on whether its claims cover the proposed generic’s labeling, formulation or manufacturing process.
Which XIFAXAN patents matter most?
The earlier rifaximin composition and polymorph patents supported the original product franchise but have approached or reached expiration. Later patents are more important because they target approved uses and the 550 mg commercial product.
Method-of-use patents can be effective against an ANDA applicant if the proposed labeling induces infringement. Formulation patents can provide a separate barrier when the generic’s tablet composition or release characteristics fall within the asserted claims.
Patent strength is therefore layered rather than dependent on a single composition patent. The estate is strongest where:
- The generic applicant seeks a label covering hepatic encephalopathy.
- The proposed product uses a formulation covered by an Orange Book-listed patent.
- The patent claims are tied to the 550 mg commercial product.
- The applicant cannot carve out the protected indication without undermining commercial viability.
What is the Orange Book status of XIFAXAN?
XIFAXAN is listed in the FDA Orange Book with patents covering the reference product and its approved uses.[4] These listings permit ANDA applicants to make patent certifications, including Paragraph IV certifications alleging that a listed patent is invalid, unenforceable or not infringed.
The Orange Book has been central to XIFAXAN’s exclusivity strategy because listed patents can trigger litigation and a 30-month stay of approval under the Hatch-Waxman Act when the brand holder sues within the statutory period.
The listing strategy has evolved as earlier patents expire and later patents become the basis for generic challenges. Commercial protection after 2024 depends primarily on the enforceability and scope of later-listed patents, not on the earliest rifaximin patents.
Which companies are challenging XIFAXAN?
Generic applicants have challenged XIFAXAN through ANDA filings and Paragraph IV certifications. Norwich Pharmaceuticals became the most prominent public challenger in litigation involving rifaximin 550 mg.
Norwich’s proposed product targeted the XIFAXAN market and prompted litigation by Salix and related entities. The dispute focused on patents covering hepatic encephalopathy treatment and the effect of Norwich’s proposed labeling.
Other generic companies may pursue separate ANDA strategies, including:
- Paragraph IV challenges to later Orange Book-listed patents.
- “Carve-out” labels excluding one protected indication.
- Launches limited to unprotected uses after patent expiration.
- Formulation designs intended to avoid asserted claims.
The number of actual launch-ready competitors may be lower than the number of patent challengers because an ANDA approval does not guarantee an immediate commercial launch.
What patent litigation affects XIFAXAN?
The most important public litigation involved Salix Pharmaceuticals and Norwich Pharmaceuticals.
Salix v. Norwich
In 2023, the U.S. Court of Appeals for the Federal Circuit affirmed key findings favoring Salix in the XIFAXAN litigation. The court upheld infringement findings involving patents directed to rifaximin treatment for hepatic encephalopathy and maintained restrictions on Norwich’s proposed generic launch.[5]
The litigation had three commercial effects:
- It delayed immediate generic entry.
- It reinforced the value of method-of-use patents.
- It preserved branded revenue while later patent protection remained in force.
The Federal Circuit decision reduced the probability of an immediate broad launch by Norwich. It did not eliminate the possibility of future challenges to other patents or alternative labeling strategies.
Settlement agreements
Publicly disclosed litigation outcomes do not establish a broad industry-wide settlement allowing unrestricted generic entry before the principal patent barriers expire. Any settlement involving confidential commercial terms could affect launch timing, authorized generic risk and the competitive intensity of the eventual market.
For valuation purposes, the critical distinction is between:
- An at-risk launch before final patent expiry.
- A licensed launch date under settlement.
- A launch after full patent expiration.
- A limited indication launch based on a label carve-out.
These scenarios produce materially different revenue curves.
When does XIFAXAN lose exclusivity?
XIFAXAN does not have a single exclusivity loss date. Its risk is staggered by patent, indication and generic strategy.
| Exclusivity layer |
Approximate timing |
Commercial significance |
| Earlier composition or polymorph protection |
2024 |
Opens broader challenge opportunities |
| Later 550 mg and use-related patents |
2029 |
Main near-term barrier to full generic competition |
| Later method or formulation patents |
2032-2034 |
Potential residual protection |
| FDA orphan-drug exclusivity |
Not the principal protection |
Patent estate is more important |
The most important practical date is the earliest date on which a generic can obtain approval and launch without violating enforceable patents. That date may be earlier than the latest listed patent expiration if the generic wins litigation or uses a permissible label carve-out. It may be later if litigation, regulatory deficiencies or manufacturing issues delay approval.
What generic launch scenarios exist for XIFAXAN?
Scenario 1: No launch until the late 2020s
This is the strongest branded outcome. Salix retains broad protection for the principal commercial indications, and generic applicants cannot obtain approval for a commercially viable label before key patents expire.
Scenario 2: Limited carve-out launch
A generic may launch with one indication removed from its labeling. This could limit initial substitution, especially if hepatic encephalopathy represents the more defensible chronic-use market.
Scenario 3: At-risk launch
A generic applicant could launch before final patent resolution. This would expose the company to damages and injunctive relief but could accelerate payer switching. Such launches are uncommon when the asserted patents have already survived significant litigation.
Scenario 4: Staggered entry
Different manufacturers could launch at different times based on separate litigation outcomes. This would produce a slower price decline than a simultaneous multi-generic launch but still pressure branded volume.
How strong is the XIFAXAN patent estate?
The estate is commercially meaningful but not risk-free.
Strengths
- Multiple patents cover different aspects of the product.
- Method-of-use claims support the hepatic encephalopathy indication.
- The Federal Circuit litigation outcome favored Salix.
- The product has two approved indications, complicating label design.
- Chronic use in hepatic encephalopathy increases the value of the protected indication.
Weaknesses
- The active ingredient is an established small molecule.
- Earlier composition protection has weakened with expiration.
- Generic applicants can challenge validity and infringement claim by claim.
- IBS-D treatment is episodic and may be more exposed to substitution.
- The value of formulation patents depends on claim breadth and bioequivalent product design.
Overall, XIFAXAN has a stronger commercial defense than a product relying on one expiring composition patent, but its long-term protection depends on later patents and litigation outcomes.
Does XIFAXAN face biosimilar risk?
No. XIFAXAN is a small-molecule rifaximin product, not a biologic. Competitors will use the ANDA generic pathway rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.
The relevant risks are generic substitution, Paragraph IV litigation, label carve-outs, authorized generic competition and potential formulation design-arounds.
Which licensing deals support XIFAXAN?
XIFAXAN is marketed by Salix, which Bausch Health acquired through its acquisition of Salix Pharmaceuticals in 2015.[6] The product was originally developed and commercialized through Salix’s gastrointestinal pharmaceutical operations.
The acquisition gave Bausch control over:
- U.S. commercialization.
- Regulatory strategy.
- Patent litigation.
- Pricing and contracting.
- Lifecycle management for hepatic encephalopathy and IBS-D.
No publicly disclosed third-party licensing arrangement currently appears to be the primary determinant of XIFAXAN’s U.S. revenue trajectory. The principal economic relationship is Bausch’s ownership and operation of Salix.
How does XIFAXAN compare with competing gastrointestinal drugs?
| Product |
Active ingredient |
Main use |
Competition profile |
| XIFAXAN |
Rifaximin |
Hepatic encephalopathy, IBS-D |
Patent-protected branded product |
| TRULANCE |
Plecanatide |
Chronic idiopathic constipation, IBS-C |
Branded prescription competition |
| LINZESS |
Linaclotide |
IBS-C, chronic constipation |
Large branded GI product |
| VIBERZI |
Eluxadoline |
IBS-D |
Different mechanism and safety profile |
| Loperamide products |
Loperamide |
Symptomatic diarrhea relief |
Low-cost OTC competition |
| Lactulose |
Lactulose |
Hepatic encephalopathy |
Older, low-cost alternative |
XIFAXAN’s closest commercial substitutes differ by indication. Lactulose remains important in hepatic encephalopathy, while loperamide and other symptomatic treatments compete in diarrhea management. None fully replicates XIFAXAN’s positioning across both approved indications.
What geographic markets matter?
The United States is the dominant value market for XIFAXAN. Patent and regulatory outcomes in the U.S. therefore have the greatest effect on Bausch’s financial trajectory.
International markets contribute less to the overall valuation because:
- Pricing is generally lower.
- Reimbursement controls are stronger.
- Patent terms differ by jurisdiction.
- Rifaximin commercialization varies by country.
- Generic competition may arrive earlier in some markets.
A global generic launch would reduce international revenue, but U.S. entry remains the primary valuation event.
Key Takeaways
- XIFAXAN generates more than $1 billion in annual U.S. revenue and is a core Bausch Health asset.
- Growth is supported by chronic hepatic encephalopathy use, repeat prescribing and the IBS-D franchise.
- The product is protected by a layered patent estate covering rifaximin composition, formulation and methods of use.
- Earlier patent protection has weakened, but later patents extend meaningful barriers into approximately 2029 and beyond.
- Norwich Pharmaceuticals’ litigation was the most important recent generic challenge, and the Federal Circuit outcome favored Salix.
- XIFAXAN faces generic, not biosimilar, risk.
- A rapid multi-generic launch would create the greatest revenue shock, while a staggered or carve-out launch would produce a slower decline.
- The principal valuation question is whether generic competition begins before or after the late-2020s patent barriers expire.
FAQs About XIFAXAN Patent and Market Risk
What is XIFAXAN’s active ingredient?
XIFAXAN contains rifaximin, a minimally absorbed rifamycin-class antibacterial drug.
Is XIFAXAN a specialty pharmaceutical?
Yes. Its principal use in hepatic encephalopathy is managed within gastroenterology, hepatology and specialty-care channels, although IBS-D prescriptions also occur in broader outpatient practice.
Can a generic company launch XIFAXAN before 2029?
Potentially, but only through a successful patent challenge, a permissible label carve-out, a settlement license or an at-risk launch. Patent expiration alone does not determine the earliest commercial entry date.
Why is hepatic encephalopathy important to XIFAXAN revenue?
It supports recurring, chronic treatment and has stronger prescription persistence than episodic IBS-D therapy. That makes the indication central to both revenue durability and patent litigation.
What would happen to XIFAXAN sales after generic entry?
Sales would likely decline through lower price, payer substitution and volume migration. The magnitude would depend on the number of entrants, launch timing, authorized generic strategy and whether competitors can market both major indications.
References
- Bausch Health Companies Inc. (2024). 2023 annual report. https://ir.bausch.com
- U.S. Food and Drug Administration. (2010). XIFAXAN approval for reduction in risk of overt hepatic encephalopathy recurrence. https://www.fda.gov
- U.S. Food and Drug Administration. (2015). XIFAXAN approval for irritable bowel syndrome with diarrhea. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov
- United States Court of Appeals for the Federal Circuit. (2023). Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc., Federal Circuit decision. https://www.cafc.uscourts.gov
- Bausch Health Companies Inc. (2015). Bausch Health completes acquisition of Salix Pharmaceuticals. https://ir.bausch.com
